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Abstract: We examined the effects of the ferrocene-based histone deacetylase-3 inhibitor Pojamide
(N1-(2-aminophenyl)-N8-ferrocenyloctanediamide) and its two derivatives N1-(2-aminophenyl)-N6-
ferrocenyladipamide and N1-(2-aminophenyl)-N8-ferroceniumoctanediamide tetrafluoroborate on
triple-negative MDA-MB-231 breast cancer cells. Viability/growth assays indicated that only the first
two compounds at 70 µM concentration caused an approximate halving of cell number after 24 h of
exposure, whereas the tetrafluoroborate derivative exerted no effect on cell survival nor proliferation.
Flow cytometric and protein blot analyses were performed on cells exposed to both Pojamide and the
ferrocenyladipamide derivative to evaluate cell cycle distribution, apoptosis/autophagy modulation,
and mitochondrial metabolic state in order to assess the cellular basis of the cytotoxic effect. The data
obtained show that the cytotoxic effect of the two deacetylase inhibitors may be ascribed to the onset
of non-apoptotic cell death conceivably linked to a down-regulation of autophagic processes and an
impairment of mitochondrial function with an increase in intracellular reactive oxygen species. Our
work expands the list of autophagy-regulating drugs and also provides a further example of the role
played by the inhibition of autophagy in breast cancer cell death. Moreover, the compounds studied
may represent attractive and promising targets for subsequent molecular modeling for anti-neoplastic
agents in malignant breast cancer.
Keywords: histone deacetylase inhibitor; breast cancer cells; cell viability; cell cycle; apoptosis;
autophagy; reactive oxygen species; mitochondrial transmembrane potential
1. Introduction
Histone deacetylases (HDAC) are enzymatic epigenetic modulators whose involvement in the
modification of chromatin structure and regulation of the activity of many non-histone proteins
is widely recognized. They are grouped into four classes on the basis of functional criteria and
homology to yeast proteins; they show distinct gene expression patterns, intracellular localization,
and role [1]. HDAC inhibition is known to affect several intracellular processes, such as gene
expression, signal transduction, and protein turnover, and to ultimately alter the proliferation, survival,
and immunogenicity of cancer cells. Within this context, HDAC inhibitors (HDACi) are an emerging
class of heterogeneous compounds that are grouped into different categories on the basis of their
chemical nature. Their specific activity may be directed to all or a broad spectrum of HDAC classes,
such as the “pan”-inhibitor SAHA, or effects may be isoform specific [2]. Although only four HDACis
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have been approved by the U.S. Food and Drug Administration, a great number of them are undergoing
clinical trials in order to thoroughly exploit their full potential as anticancer agents [3,4]. Increasing
knowledge of the distinct pathways that are more specifically involved in tumor growth or metastasis
in different neoplastic histotypes has emphasized the need to develop selective agents that target
individual HDACs and the investigation, at the molecular level, of the biological response to such
selective inhibitors by cancer cells.
Triple-negative breast cancers (TNBC) do not show estrogen and progesterone receptor expression.
Also being HER2/neu negative, they are refractive toward hormone-based therapies and to drugs
that target HER2. This renders the TNBC cytotype particularly “aggressive” and potentially highly
malignant, thereby being associated usually with a worse prognosis than other breast tumor types [5].
The limitation of treatment options against TNBC has prompted the development of novel compounds
or analogs of pre-existing compounds that might counteract neoplastic cell growth but that, conversely,
require substantial biological characterization. The MDA-MB-231 cell line has been selected as a model
system herein. It originates from a pleural effusion of a basal subtype TNBC and exhibits many aspects
of a highly malignant phenotype, such as the inactivation of p53 due to a mutation in codon 280 of
exon 8 and the ability to form metastases in vivo [6–8].
In a previous publication, we [9] reported the synthesis of the novel HDACi Pojamide
(N1-(2-aminophenyl)-N8-ferrocenyloctanediamide, 1), a ferrocene-containing o-aminoanilide that
can be activated in cells to a FeIII species. This compound displays an optimal arrangement of a
ferrocene cap—which can be oxidized—a linker, and a benzamide zinc-binding motif, as opposed
to the more common hydroxamic acid, to enable selective inhibitory activity toward HDAC3, one
of the major class I HDACs. Overexpression of this isoform has been reported in a broad range of
neoplastic histotypes, and its activity was found related to a variety of aspects of tumor progression.
In particular, in TNBC, it appeared to be involved in stimulating cell migration and maintaining
the cancer stem cell subpopulation via the Akt–GSK3β–β-catenin signaling pathway [10,11]. The
goal of the present study was to thoroughly examine the effects of 1 on TNBC cells of the
MDA-MB-231 line with respect to viability and proliferation, cell cycle distribution, apoptosis and
autophagy modulation, and mitochondrial metabolic/cell redox state. In addition, a comparative
evaluation was made with two derivatives of 1: N1-(2-aminophenyl)-N6-ferrocenyladipamide (2) and
N1-(2-aminophenyl)-N8-ferroceniumoctanediamide tetrafluoroborate (3) (Figure 1). Compound 2
contains a four-carbon aliphatic chain, thereby resulting in a shorter “linker” portion of the molecule
with a slightly shifted enzyme docking with respect to 1 and, as a consequence, weaker HDAC3
activity. Compound 3 is a preformed, independently synthesized, oxidized analog of 1. Such a FeIII
derivative is postulated to be formed in 1-treated cells when sodium nitroprusside oxidant is added,
but it is a charged species and, therefore, is supposedly poorly permeable in cells if administered
exogenously [9].
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Figure 1. Compounds used in the present study.
2. Results
In the first set of experiments, we checked the effect of dose- and time-dependent incubation
with either 1, 2, or 3 on MDA-MB-231 cell viability via direct cell counting and MTS assay. As shown
in Figure 2, when cells were exposed for 24 h to 1 and 2, these compounds caused a decrease in cell
number starting from 10 nm and 10 µM concentrations for 1 and 2, respectively. A dose–response
U-shaped curve is evident with a maximal effect equal to 70 µM for both compounds, among the
concentrations tested. Since exposure to the two molecules for longer times (i.e., 48 and 72 h) did not
appear to substantially modify the effect observed after 24 h of incubation, the concentration of 70 µM
and the duration of exposure of 24 h were chosen for all the subsequent biochemical experiments.
On the other hand, exposure to 3 at any concentration tested did not exert significant effects on
MDA-MB-231 cell viability and, therefore, this compound was not submitted to further analyses.
For comparative and more detailed insight into the cytotoxic action of 1 and 2 on triple-negative
MDA-MB-231 cells, cell cycle state, apoptosis induction markers (phosphatidylserine externalization
and caspase 8 activation), autophagy markers (quantitation of acidic vesicular organelles (AVOs),
and intracellular accumulation of p62/Sequestosome-1 (SQSTM1), Beclin-1 and microtubule-associated
protein light chain-3 (LC3)-I and -II), and markers of mitochondrial metabolism/cell redox state
(mitochondrial transmembrane potential (MMP) and reactive oxygen species (ROS) production)
were studied.
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Figure 2. Effect of 24 h incubation with 1, 2, and 3 on the viability of MDA-MB-231 cells.
(A) Dose–response bars from quadruplicate cell counting assays. (B) Dose–response bars from
quadruplicate MTS assays. Four replicates were run for each assay. The results are expressed as
the mean ± standard error of the mean (SEM). * p < 0.05.
First, in order to study the effects induced by treatment with 1 and 2 on MDA-MB-231 cell cycle,
cells treated with the HDACi for 24 h were stained with propidium iodide and studied by flow
cytometric analysis for the distribution of cell cycle phases. Figure 3 shows that exposure to both 1
and 2 was chiefly linked with a higher percentage of cells in the pre-G0 fraction (44.1% and 43.1%,
respectively, vs. 22.6% of control), consistent with an increase in damaged and fragmented cells due to
cytotoxicity of the compounds.
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Figure 3. Cell cycle distribution of MDA-MB-231 cells exposed to 1 and 2, compared to control
conditions. The results are expressed as the mean ± SEM. of triplicate assays. Four replicates were run
for each assay. All p values were <0.05 if compared to controls.
A more or less pronounced decrease in the cell fractions was found in the other cell cycle phases:
in particular, the G0/G1 phase fraction of 1 and 2 accounted for 55.4% and 56%, respectively, vs. 67.3%
of control, the S phase fraction for 0.4% and 0.8%, respectively, vs. 3% of control, and the G2/M phase
fraction for 0.1% for both molecules vs. 6.6% of control.
In the second set of experiments, the onset of apoptosis, if any, in samples of control and 1- or
2-treated cells was checked through two different assays having phosphatidylserine externalization
and caspase-8 activation as endpoints. As shown in Figure 4, data from both assays showed no
difference between control and exposed cells, confirming that programmed cell death was not involved
in 1 and 2 cytotoxicity after 24 h treatment. Comparable results were obtained with shorter exposure
to the compounds (6 and 12 h).
It is known that the autophagy rate of MDA-MB-231 cells is constitutively high [12], hereby
furnishing cells with energy and the basic elements in order to counterbalance the metabolic stress due
to oxygen and nutrient shortage during fast proliferation. Moreover, it is recognized that autophagy
down-regulation sensitizes MDA-MB-231 tumor cells to the cytotoxic effect of chemical and physical
agents [13,14]. Therefore, we firstly checked via acridine orange staining whether 1 and 2 might lead
to a modification in autolysosome numbers, also known as AVOs, a hallmark of autophagy. Figure 5
shows that 1-treated cells led consistently to a reduction in the amount and size of AVOs whereas
exposure to 2 showed a more limited decrease compared to the control (1 vs. 2 vs. control = 76.11% vs.
95.16% vs. 99.97%).
Autophagy modulation by 1 and 2 treatment was also verified via molecular markers through
protein blot analysis of the intracellular accumulation levels of Beclin-1 and p62/ SQSTM1, whose
variations are used to monitor the onset of autophagy, and of the conversion of LC3 from its
cytosolic form (LC3-I) to its autophagosome-associated lipidated form (LC3-II), which can be identified
electrophoretically due to its lower molecular mass [15]. The immunoblots and the histograms in
Figure 6 show that the accumulation of autophagy markers is modified by exposure to the compounds.
In particular, p62/SQSTM1 amount appears to increase after 24 h of incubation with 1 and 2 although
in the latter case the augmentation is fainter. In parallel, the amount of Beclin-1 decreases, more
prominently in the presence of 2, and LC3-II/LC-3I ratio increases in HDACi-treated cells with respect
to the control.
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Figure 4. Representative flow cytometric assays for apoptosis in MDA-MB-231 cells cultured in control
conditions or exposed to either 1 or 2 for 24 h. Evaluations of the extent of (A) caspase-8 activation
using the Vybrant®FAM Caspase-8 Assay Kit, and (B) phosphatidylserine externalization using the
Annexin V apoptosis Detection Kit. In (B), the dot plots show the result of a representative experiment
and the percentages indicated in the left and right quadrants refer to live annexin V-/propidium iodide
cells and early apoptotic annexin V+/propidium iodide cells, respectively. The results are expressed as
the mean ± SEM of triplicate assays.
Figure 5. Representative flow cytometric analyses of AVO accumulation in MDA-MB-231 cells cultured
in control conditions or exposed to either 1 or 2 for 24 h. The percentage indicated in the top quadrants
refers to AVO-positive cells. The dot plots show the result of a representative experiment. The results
are expressed as the mean ± SEM of triplicate assays.
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Figure 6. (A) Representative immunoblot analysis of autophagy molecular markers in MDA-MB-231
cells cultured in control conditions or exposed to either 1 or 2 for 24 h. (B) Histograms showing the
relative extent of marker quantitation after normalization with actin as the loading control. The results
are expressed as the mean ± SEM of triplicate assays. All p values were <0.05 if compared to controls.
Variations in MMP levels following cell exposure to the drugs were verified using the JC1 probe.
As shown in Figure 7, flow cytometry analysis evidences a loss of MMP in treated cells, the percentage
of low red-emitting cells (bottom quadrant) being about 75% and 81% after 24 h of exposure to 1 and
2, respectively, vs. approximately 5% of control cells. It is known that the oxidative damage caused
by excess ROS may impair cell cycle progression and direct cells to death [16]. Thus, the ability of 1
and 2 to impair mitochondrial activity was also assessed via evaluation of ROS production. As shown
in Figure 8, a 24-h exposure to 1 and 2 resulted in an increase in total intracellular ROS of about 4.6-
and 5.2-fold vs. controls, comparable to that obtained with treatment with H2O2 as a positive control
(about 4.8-fold).
Figure 7. Representative flow cytometric analysis of MMP in MDA-MB-231 cells cultured in control
conditions, or exposed to either valinomycin (as a positive control), 1, or 2 for 24 h. The percentages
indicated in the bottom quadrants in each frame quantitate the amount of low red-emitting cells that
underwent dissipation of MMP. The results are expressed as the mean ± SEM of triplicate assays.
Int. J. Mol. Sci. 2019, 20, 804 8 of 14
Figure 8. Representative histograms showing ROS generation in MDA-MB-231 cells cultured in
control conditions or exposed to either H2O2 (as a positive control), 1, or 2 for 24 h. The x-axis
reports the intensity of green fluorescence emitted by the dye 2’,7’-dichlorodihydrofluorescein, which
is proportional to the amount of cytosolic ROS. The fluorescence percentages of the gated regions H-1
and H-2 of the histograms are reported under the graphs. The results are expressed as the mean ± SEM
of triplicate assays.
3. Discussion
In the present paper, we have tested the cytotoxic effect on TNBC MDA-MB-231 cells of the
ferrocene-containing HDACi 1 and its derivative 2, already validated for their in vitro inhibitory
activity on HDAC3 [9]. In the same article, biological assays were performed by exposing Xenopus laevis
embryos and HDAC3-overexpressing cervical and colon cancer cell lines (HeLa, Ht-29, and HCT-113)
to 1 and 2. The results obtained highlighted the powerful activity of 1 vs. 2 in maintaining the
acetylation of H4K12ac in the embryo and preventing HCT-113 cellular invasion at low concentration
(1 µM). On the other hand, a moderate effect on the inhibition of cancer cell proliferation and colony
formation was found for 1 at about ten-fold higher concentration whereas 2 was ineffective. Concerning
compound 3, the ferrocenium salt was found to affect HCT-113 colony formation poorly, with its
activity being about 100-fold lower than that of 1 presumably due to its scarce intracellular uptake.
Further confirmation of its meager inhibitory activity has been obtained here with MDA-MB-231 cells,
thereby preventing additional molecular investigation on its biological effects.
Our data indicate that both compounds exert a cytotoxic effect on MDA-MB-231 cells prominently
when administered at 70 µM concentration for 24 h. Interestingly, the dose–response curve appeared
to be of the “U-shape” or hormetic type. Such curves have precedence in anticancer assays [17],
being attributable to various causes such as the formation of intra- or extracellular complexes or the
inactivation of intracellular pathways responsible of the biological activity at elevated concentrations of
the drugs [18]. Further studies are required to clarify this issue as regards the compounds under study.
Treatment with 1 and 2 produced significant accumulation of MDA-MB-231 cells at the pre-G0/G1
cell cycle phase, which was accompanied by a decrease at the other phases, mostly S and G2/M.
However, no phosphatidylserine externalization and caspase-8 activation was found using specific
assays, thereby indicating that the cytotoxic effect of the two compounds might be ascribed to the
onset of non-apoptotic cell death, as also reported for exposure of MDA-MB-231 cells to another
ferrocene-containing class I HDACi (e.g., JAHA) [19] and exposure of other tumor cell model systems
to the aryl-capped SAHA or depsipeptide [20]. It is worth mentioning that MDA-MB-231 cells possess
a mutant p53, which sustains survival, and elevated levels of the apoptosis-suppressor phospholipase
D, thereby being resistant to programmed cell death [21,22].
The most intriguing results on the mechanisms of action of 1 and 2 concern their ability to induce
autophagy inhibition and ROS production/MMP dissipation. The data presented here suggest that 1
and 2 can be included in the list of those molecules that down-regulate autophagy, thereby depriving
TNBC cells of such a pro-survival mechanism. In particular, flow cytometry results showed a massive
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reduction in AVO number and size when cells were treated with 1, whereas exposure to 2 resulted
in a slightly lower AVO accumulation and extension than that of control. When autophagy markers
were evaluated electrophoretically, the amount of p62/SQSTM1 appeared to markedly increase after
24 h incubation with 1, remaining somewhat higher than the control in the case of exposure to 2.
Moreover, there was a reduction in the accumulation levels of Beclin-1 following exposure to both
HDACis. According to the data published by [23], an increase in the p62/Beclin-1 ratio (average values
= 0.63 for control and 1.08 for 1) is closely linked to the inhibition of the autophagic process. On the
other hand, also in the case of cells exposed to 2, the p62/Beclin-1 ratio showed a sizeable increase
(average value = 1.18) although the intensity of fluorescence emitted by acridine orange-stained AVOs
did not appear greatly modified with respect to control. It is known that acridine orange is taken
up not only by autolysosomes but also by the amount of heterolysosomes present; however, it is not
a good marker of the earlier autophagosomes [24]. Therefore, if the increase in p62/Beclin-1 ratio
is indicative of autophagy inhibition, it is conceivable that the lack of prominent modifications in
flow cytometry analyses might be due to the fact that the heterophagic activity in cells exposed to 2
remains unmodified or may even rise. Conversely, the data obtained after treatment with 1 suggest
a generalized down-regulation of the intracellular degradation systems. Regarding the LC3 marker,
the LC3-II/LC3-I ratio appeared to increase in MDA-MB-231 cells exposed to both HDACis vs. control.
LC3-II accumulation is related to autophagosome maturation, which, once completed, results in the
activation of autophagy and the degradation of LC3. As suggested by [24], up-regulation of the
LC3-II/LC3-I ratio might be linked to a failure of autophagosome maturation and turnover likely
due to a delay or impairment of the lysosomal degradation process, thus, further substantiating the
inhibitory effect exerted by 1 and 2 on the occurrence of autophagy when administered to the TNBC
cells under study.
Both treatments were effective in inducing the dissipation of MMP and an increase in the levels of
ROS. It is known that ROS are by-products of mitochondrial respiration, which impairs intracellular
signaling and also induces oxidative damage. Cells possess enzymatic and non-enzymatic antioxidant
defense systems that counterbalance ROS accumulation and are involved in the maintenance of redox
homeostasis [25]. The amount of intracellular ROS increases due to an imbalance of ROS production,
removal, and extramitochondrial release. Conceivably, treatment of MDA-MB-231 cells with 1 and 2
induces oxidative stress likely due to the interruption of redox homeostasis from structural impairments
of the mitochondria and/or loss of matrix solutes (e.g., glutathione) from an increase in their membrane
permeability. Moreover, ROS production may further damage the mitochondria, thus initiating a
vicious cycle leading to the exacerbation of ROS formation, mitochondrial dysfunction, and MMP
collapse as reported in various papers [26,27], including the present one. It is also acknowledged
that mitochondria play a crucial and complex role in autophagy. In particular, some authors [28,29]
reported that the accumulation of MMP-deficient mitochondria impairs cellular autophagic activity
and autophagosome turnover possibly through reduced lysosomal acidification, which ultimately
leads to cell death. In light of the evidence produced in our work, it is conceivable that the cytotoxic
activity of the HDACis tested on TNBC cells relies, at least partly, on the onset of oxidative damage
and autophagy inhibition.
Further studies will be required to determine the precise cellular pathways through which 1
and 2 accomplish their TNBC cell death activity, particularly since our data suggest that the activity
of compound 2 is conceivably HDAC independent. Nonetheless, our work on compounds 1 and 2
presents interesting aspects in that it expands the list of autophagy-regulating drugs and provides
more insight into the role played by autophagy inhibition in breast cancer cell death. Interestingly,
the HDACi 2 that was poorly active on different biological models (i.e., Xenopus laevis embryo cells and
non-breast-derived malignant cancer cells, as reported by [9]) was equipotent to the parental molecule
1 toward TNBC cells, thus further underlining the importance of thorough biological characterization
of bioinorganic HDAC probes in different cell model systems. A limitation of this study could be
the high concentration (70 µM) of the HDACis, which was required to approximately halve the cell
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population in the in vitro system used. In fact, the IC50 value of most HDACis active on MDA-MB-231
cells is attested to be between 4 and 10 µM [20,30,31]. This differing potency might be explained by
the specific HDAC selectivity of the compounds tested here. In fact, our results are in line with those
obtained by Bian et al. [32] who demonstrated that solid tumor cell lines, such as MDA-MB-231, are less
sensitive than hematologic cell lines to the anti-proliferative effect exerted by the selective HDAC2 and
-3 inhibitor N-hydroxy-4-(1H-indol-3-yl) butanamide; its IC50 at 48 h for these cells being about 30 µM.
Moreover, poor cell permeation and high lipophilicity might also lead to the high concentrations
needed for the biological effect.
In summary, here we have shown that ferrocene-containing HDACis 1 and 2 are inhibitors of
TNBC cell viability and growth in culture operating an impairment on cell autophagic process and
mitochondrial function. The compounds studied may represent attractive and promising targets
for following molecular modeling for anti-neoplastic agents in malignant breast cancer with the
aim of their further optimization in terms of potentiation of cytotoxic activity and improvement
of effectiveness.
4. Materials and Methods
4.1. Cell Culture and HDACis
MDA-MB-231 TNBC cells were cultured in D-MEM medium plus 10% fetal calf serum (FCS),
100 U/mL penicillin, 100 µg/mL streptomycin, and 2.5 mg/L amphotericin B (Sigma, St. Louis, MO,
USA) at 37◦C in a 5% CO2 atmosphere. The cells were detached from flasks with 0.05% trypsin-EDTA,
counted, and plated at the necessary density for treatment once they had achieved 60%–80% confluency.
Compounds 1, 2, and 3 were synthesized as reported by [9], dissolved in dimethyl sulfoxide
(DMSO) as stock solutions and stored at room temperature until use.
4.2. Cell Viability Assays
The in vitro cytotoxic activity was evaluated with (i) direct cell counting and (ii) the MTS-based
CellTiter96®AQueous One Solution Cell Proliferation Assay (Promega Italia, Milan, Italy) according
to manufacturer’s instructions. Briefly, MDA-MB-231 cells in exponential growth were plated at a
concentration of 5,500 cells/well in a 96-well plate and left to adhere overnight. Next, cells were
treated with either 100 nM, 1, 10, 50, 70, or 100 µM of each compound or with DMSO vehicle for 24, 48,
and 72 h and processed for the viability assay. Direct cell counting was performed in a Bürker chamber
after trypan blue staining of trypsinized cells. For the MTS assay, after the addition of 20 µL of MTS
reagent to each well, the absorbance of the dye was measured in an automated microplate reader at
490 nm. Cell viability ratios relate to the ratio between treated cells and untreated controls.
4.3. Flow Cytometry
Flow cytometric assays were performed according to [12]. The occurrence of apoptosis was
checked with both the Annexin V-FITC kit (Canvax Biotech, Cordoba, Spain) which monitors the rate of
externalization of phosphatidylserine, and the Vybrant® FAM Caspase-8 Assay Kit (Molecular Probes,
Eugene, OR, USA), which monitors the extent of activation of caspase-8, following the manufacturer’s
instructions. Data were represented as dot plots using Flowing Software v.2.5.1., which discriminates
normal cells (bottom left quadrant) from those undergoing early apoptosis (bottom right quadrant)
or those undergoing late apoptosis/necrosis (top right quadrant).
The production of ROS was assessed with the ROS Detection Assay Kit (Canvax Biotech) following
the manufacturer’s instructions. A H2O2-treated positive control was included in the analysis, and data
were represented as histograms using Flowing Software v.2.5.1.
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MMP was checked with the fluorescent dye JC1 (Molecular Probes), which is selectively
internalized by mitochondria. In the case that of intact MMP and it polymerizes, the fluorescence
emission shifts from green (~529 nm) to red (~590 nm). In the case of MMP dissipation and it remains
as a monomer, the red/green fluorescence intensity ratio decreases. A positive control obtained by
co-incubation of JC1 with 1 mg ionophore valinomycin (Sigma)/mL, which induces mitochondrial
gradient dissipation, was included in the analysis. Data were represented as dot plots using Flowing
Software v.2.5.1., which discriminates in the bottom quadrant the number of cells that undergo a loss
of MMP.
Quantification of AVOs was enabled by staining with acridine orange, a cell-permeable fluorescent
dye that is taken up, protonated, and sequestered in the acidic compartments. Cells were fixed with
cold 70% ethanol and incubated with 100 µg acridine orange/mL (Sigma) for 20 min in the dark before
analysis. Data were represented as dot plots using Flowing Software v.2.5.1., which discriminate cells
with increased AVO accumulation in the top quadrant.
Cell cycle distributions were evaluated by propidium iodide staining; following pre-incubation
(Triton X-100 and RNase A (Sigma)), they were analyzed using Weasel v.3.0.1. software.
All the preparations assayed contained both attached and floating cells, and all the analyses were
performed in a FACSCanto apparatus (BD Biosciences, Franklin Lakes, NJ, USA).
4.4. Protein Blot
Electrophoretic analysis and immunoblots were performed following [20]. Lysates of control
and treated cells were submitted to 13% SDS-PAGE and then protein transfer onto Hybond-ECL
nitrocellulose membranes (GE Healthcare, Piscataway, NJ, USA) in a Novablot semidry apparatus
(Pharmacia, Stockholm, Sweden). The primary antibodies used for immuno-detection were: rabbit
polyclonal anti-Beclin-1 antibody (H-300, sc-11427, Santa Cruz Biotechnology, Dallas, TX, USA;
working dilution 1:1000), rabbit polyclonal anti-LC3 antibody (L8918, Sigma; working dilution
1:750), rabbit polyclonal anti-p62/SQSTM1 (P0068, Sigma; working dilution 1:1000), and rabbit
polyclonal anti-actin antibody (A5060, Sigma; working dilution 1:500). The latter antibody was
used for a loading control. The secondary antibody was a horseradish peroxidase-conjugated
anti-rabbit IgG antibody (NA934V, GE Healthcare; working dilution 1:2500). Protein bands were
visualized in a Versadoc MP4000 molecular digital imaging system (Bio-Rad, Hercules, CA, USA)
using the Immun-Star WesternC Chemiluminescent Kit (Bio-Rad), and analyzed by ImageJ software.
Quantitation was performed after normalization of the signals with respect to those obtained with
anti-actin antibody reaction.
4.5. Statistics
Statistics were checked through ANOVA test with SigmaStat 4.0 software (SYSTAT, San Jose, CA,
USA). A p-value <0.05 was considered statistically significant.
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Abbreviations
HDACi histone deacetylase inhibitor
SAHA suberoylanilide hydroxamic acid
TNBC triple-negative breast cancer
HER2 human epidermal growth factor receptor 2
GSK3β glycogen synthase kinase 3 beta
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
AVO acidic vesicular organelle
SQSTM1 sequestosome-1
LC3 microtubule-associated proteins 1A/1B light chain 3B
MMP mitochondrial transmembrane potential
ROS reactive oxygen species
H4K12ac acetylated histone H4 at lysine 12
JAHA Jay Amin hydroxamic acid (N1-(ferrocenyl)-N8-hydroxyoctanediamide)
IC50 half maximal inhibitory concentration
D-MEM Dulbecco’s Modified Eagle Medium
EDTA ethylenediaminetetraacetic acid
DMSO dimethyl sulfoxide
FITC fluorescein isothiocyanate
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
ECL enhanced chemiluminescence
ANOVA analysis of variance
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